The FDA has granted regulatory approval for tirzepatide as an adjunct to lifestyle intervention for adults with chronic obesity.
Investigational compound Tirzepatide operates primarily through target receptor pathways (Dual GIP and GLP-1 receptor co-agonism).
In a landmark regulatory milestone, the US Food and Drug Administration approved tirzepatide for chronic weight management in adults with obesity or overweight and at least one weight-related condition.
The approval comes on the strength of results from the SURMOUNT clinical trial program, where participants receiving the highest approved dose of tirzepatide achieved an average of over 20% total body weight reduction in conjunction with lifestyle modifications.
Dual receptor co-agonism demonstrates that synergistic activation of glucose-dependent insulinotropic polypeptide (GIP) pathways enhances GLP-1 mediated metabolic control while improving tolerability.
Deepen your investigation across interconnected clinical trials, bioactive profiles, mechanistic knowledge guides, and regulatory updates.
Multinational phase 3 trial establishing substantial and sustained body-weight reductions of up to 20.9% with dual GIP/GLP-1 receptor co-agonist tirzepatide.
Head-to-head phase 3 trial demonstrating that the dual GIP/GLP-1 receptor co-agonist tirzepatide achieved superior glycemic control and weight reduction compared to semaglutide 1 mg.
The landmark SELECT trial establishing a statistically significant 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic patients treated with once-weekly semaglutide.
Landmark phase 2 trial published in the New England Journal of Medicine demonstrating unprecedented weight reduction of up to 24.2% over 48 weeks with the GIP/GLP-1/Glucagon triple agonist retatrutide.
Why do some peptides degrade in minutes while others circulate for days? Exploring enzymatic cleavage, renal filtration, albumin binding, and chemical half-life engineering.
How seven-transmembrane receptors transduce extracellular peptide docking into intracellular second-messenger cascades (cAMP, IP3, and calcium flux).
A step-by-step educational guide to reading standard volumetric syringe units and accurately translating syringe ticks into precise mass measurements.
Dual and triple receptor agonists demonstrate potent anti-fibrotic and lipid-clearing actions in phase 2 trials targeting non-alcoholic fatty liver disease.
Peer-reviewed Phase 2 trial data in NEJM demonstrates substantial dose-dependent body weight reductions of up to 24.2% with the GIP/GLP-1/Glucagon triple agonist retatrutide.
Multinational clinical data confirms that once-weekly semaglutide reduces major adverse cardiovascular events by 20% in non-diabetic adults with obesity and cardiovascular disease.
Browse therapeutics categorized by targeted physiological domains including Metabolic Health, Longevity, Tissue Repair, and Neurobiology.
